Skip to main content
Top
Published in: European Radiology 1/2019

01-01-2019 | Oncology

Gliosarcoma: a clinical and radiological analysis of 48 cases

Authors: Xiaoping Yi, Hang Cao, Haiyun Tang, Guanghui Gong, Zhongliang Hu, Weihua Liao, Lunquan Sun, Bihong T. Chen, Xuejun Li

Published in: European Radiology | Issue 1/2019

Login to get access

Abstract

Objectives

To retrospectively review the radiological and clinicopathological features of gliosarcoma (GSM) and differentiate it from glioblastoma multiforme (GBM).

Methods

The clinicopathological data and imaging findings (including VASARI analysis) of 48 surgically and pathologically confirmed GSM patients (group 1) were reviewed in detail, and were compared with that of other glioblastoma (GBM) cases in our hospital (group 2).

Results

There were 28 men and 20 women GSM patients with a median age of 52.5 years (range, 24-80 years) in this study. Haemorrhage (n = 21), a salt-and-pepper sign on T2-weighted images (n = 36), unevenly thickened wall (n = 36) even appearing as a paliform pattern (n = 32), an intra-tumoural large feeding artery (n = 32) and an eccentric cystic portion (ECP) (n = 19) were more commonly observed in the GSM group than in GBM patients. Based on our experience, GSM can be divided into four subtypes according to magnetic resonance imaging (MRI) features. When compared to GBM (group 2), there were more patients designated with type III lesions (having very unevenly thickened walls) and IV (solid) lesions among the GSM cases (group 1). On univariate prognostic analysis, adjuvant therapy (radiotherapy, chemotherapy, and radiochemotherapy) and existence of an eccentric cyst region were prognostic factors. However, Cox's regression model showed only adjuvant therapy as a prognostic factor for GSM.

Conclusions

When compared to GBM, certain imaging features are more likely to occur in GSM, which may help raise the possibility of this disease. All GSM patients are recommended to receive adjuvant therapy to achieve a better prognosis with radiotherapy, chemotherapy or radiochemotherapy all as options.

Key Points

• Diagnosis of gliosarcoma can be suggested preoperatively by imaging.
• Gliosarcoma can be divided into four subtypes based on MRI.
• Paliform pattern and ECP tend to present in gliosarcoma more than GBM.
• The cystic subtype of gliosarcoma may predict a more dismal prognosis.
• All gliosarcoma patients should receive adjuvant therapy to achieve better prognosis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Buckner JC, Ballman KV, Michalak JC et al (2006) Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials. J Clin Oncol 24:3871–3879CrossRef Buckner JC, Ballman KV, Michalak JC et al (2006) Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials. J Clin Oncol 24:3871–3879CrossRef
2.
go back to reference Kozak KR, Mahadevan A, Moody JS (2009) Adult gliosarcoma: epidemiology, natural history, and factors associated with outcome. Neuro Oncol 11:183–191CrossRef Kozak KR, Mahadevan A, Moody JS (2009) Adult gliosarcoma: epidemiology, natural history, and factors associated with outcome. Neuro Oncol 11:183–191CrossRef
3.
go back to reference Han SJ, Yang I, Tihan T, Prados MD, Parsa AT (2010) Primary gliosarcoma: key clinical and pathologic distinctions from glioblastoma with implications as a unique oncologic entity. J Neurooncol 96:313–320 Han SJ, Yang I, Tihan T, Prados MD, Parsa AT (2010) Primary gliosarcoma: key clinical and pathologic distinctions from glioblastoma with implications as a unique oncologic entity. J Neurooncol 96:313–320
4.
go back to reference Walker GV, Gilbert MR, Prabhu SS, Brown PD, McAleer MF (2013) Temozolomide use in adult patients with gliosarcoma: an evolving clinical practice. J Neurooncol 112:83–89 Walker GV, Gilbert MR, Prabhu SS, Brown PD, McAleer MF (2013) Temozolomide use in adult patients with gliosarcoma: an evolving clinical practice. J Neurooncol 112:83–89
5.
go back to reference Frandsen J, Orton A, Jensen R et al (2017) Patterns of care and outcomes in gliosarcoma: an analysis of the National Cancer Database. J Neurosurg 21:1–6 Frandsen J, Orton A, Jensen R et al (2017) Patterns of care and outcomes in gliosarcoma: an analysis of the National Cancer Database. J Neurosurg 21:1–6
6.
go back to reference Sampaio L, Linhares P, Fonseca J (2017) Detailed magnetic resonance imaging features of a case series of primary gliosarcoma. Neuroradiol J 30:546–553CrossRef Sampaio L, Linhares P, Fonseca J (2017) Detailed magnetic resonance imaging features of a case series of primary gliosarcoma. Neuroradiol J 30:546–553CrossRef
7.
go back to reference Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131:803–820CrossRef Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131:803–820CrossRef
8.
go back to reference Damodaran O, van Heerden J, Nowak AK et al (2014) Clinical management and survival outcomes of gliosarcomas in the era of multimodality therapy. J Clin Neurosci 21:478–481CrossRef Damodaran O, van Heerden J, Nowak AK et al (2014) Clinical management and survival outcomes of gliosarcomas in the era of multimodality therapy. J Clin Neurosci 21:478–481CrossRef
9.
go back to reference Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466CrossRef Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466CrossRef
10.
go back to reference Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996CrossRef Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996CrossRef
11.
go back to reference Cao H, Wang F, Li XJ (2017) Future strategies on glioma research: from big data to the clinic. Genomics Proteomics Bioinformatics 15:263–265CrossRef Cao H, Wang F, Li XJ (2017) Future strategies on glioma research: from big data to the clinic. Genomics Proteomics Bioinformatics 15:263–265CrossRef
12.
go back to reference Liao W, Liu Y, Wang X et al (2009) Differentiation of primary central nervous system lymphoma and high-grade glioma with dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging. Acta Radiol 50:217–225CrossRef Liao W, Liu Y, Wang X et al (2009) Differentiation of primary central nervous system lymphoma and high-grade glioma with dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging. Acta Radiol 50:217–225CrossRef
13.
go back to reference Chang K, Bai HX, Zhou H et al (2017) Residual convolutional neural network for determination of IDH status in low- and high-grade gliomas from MR imaging. Clin Cancer Res 2018, 24(5):1073-1081. Chang K, Bai HX, Zhou H et al (2017) Residual convolutional neural network for determination of IDH status in low- and high-grade gliomas from MR imaging. Clin Cancer Res 2018, 24(5):1073-1081.
14.
go back to reference Zhou H, Vallières M, Bai HX et al (2017) MRI features predict survival and molecular markers in diffuse lower-grade gliomas. Neuro-Oncology 19:862–870CrossRef Zhou H, Vallières M, Bai HX et al (2017) MRI features predict survival and molecular markers in diffuse lower-grade gliomas. Neuro-Oncology 19:862–870CrossRef
15.
go back to reference Wanggou S, Feng C, Xie Y, Ye L, Wang F, Li X (2016) Sample level enrichment analysis of KEGG pathways identifies clinically relevant subtypes of glioblastoma. J Cancer 7:1701–1710CrossRef Wanggou S, Feng C, Xie Y, Ye L, Wang F, Li X (2016) Sample level enrichment analysis of KEGG pathways identifies clinically relevant subtypes of glioblastoma. J Cancer 7:1701–1710CrossRef
16.
go back to reference Singh G, Das KK, Sharma P et al (2015) Cerebral gliosarcoma: analysis of 16 patients and review of literature. Asian J Neurosurg 10:195–202CrossRef Singh G, Das KK, Sharma P et al (2015) Cerebral gliosarcoma: analysis of 16 patients and review of literature. Asian J Neurosurg 10:195–202CrossRef
17.
go back to reference Maiuri F, Stella L, Benvenuti D, Giamundo A, Pettinato G (1990) Cerebral gliosarcomas: correlation of computed tomographic findings, surgical aspect, pathological features, and prognosis. Neurosurgery 26:261–267CrossRef Maiuri F, Stella L, Benvenuti D, Giamundo A, Pettinato G (1990) Cerebral gliosarcomas: correlation of computed tomographic findings, surgical aspect, pathological features, and prognosis. Neurosurgery 26:261–267CrossRef
18.
go back to reference di Norcia V, Piccirilli M, Giangaspero F, Salvati M (2008) Gliosarcomas in the elderly: analysis of 7 cases and clinico-pathological remarks. Tumori 94:493–496CrossRef di Norcia V, Piccirilli M, Giangaspero F, Salvati M (2008) Gliosarcomas in the elderly: analysis of 7 cases and clinico-pathological remarks. Tumori 94:493–496CrossRef
19.
go back to reference Han L, Zhang X, Qiu S et al (2008) Magnetic resonance imaging of primary cerebral gliosarcoma: a report of 15 cases. Acta Radiol 49:1058–1067CrossRef Han L, Zhang X, Qiu S et al (2008) Magnetic resonance imaging of primary cerebral gliosarcoma: a report of 15 cases. Acta Radiol 49:1058–1067CrossRef
20.
go back to reference Meis JM, Martz KL, Nelson JS (1991) Mixed glioblastoma multiforme and sarcoma. A clinicopathologic study of 26 radiation therapy oncology group cases. Cancer 67:2342–2349CrossRef Meis JM, Martz KL, Nelson JS (1991) Mixed glioblastoma multiforme and sarcoma. A clinicopathologic study of 26 radiation therapy oncology group cases. Cancer 67:2342–2349CrossRef
21.
go back to reference Zhang BY, Chen H, Geng DY et al (2011) Computed tomography and magnetic resonance features of gliosarcoma: a study of 54 cases. J Comput Assist Tomogr 35:667–673CrossRef Zhang BY, Chen H, Geng DY et al (2011) Computed tomography and magnetic resonance features of gliosarcoma: a study of 54 cases. J Comput Assist Tomogr 35:667–673CrossRef
23.
go back to reference Machuca TN, Prevedello DM, Pope LZ, Haratz SS, Araújo JC, Torres LF (2004) Gliosarcoma: report of four cases with immunohistochemical findings. Arq Neuropsiquiatr 62:608–612CrossRef Machuca TN, Prevedello DM, Pope LZ, Haratz SS, Araújo JC, Torres LF (2004) Gliosarcoma: report of four cases with immunohistochemical findings. Arq Neuropsiquiatr 62:608–612CrossRef
24.
go back to reference Lutterbach J, Guttenberger R, Pagenstecher A (2001) Gliosarcoma: a clinical study. Radiother Oncol 61:57–64CrossRef Lutterbach J, Guttenberger R, Pagenstecher A (2001) Gliosarcoma: a clinical study. Radiother Oncol 61:57–64CrossRef
Metadata
Title
Gliosarcoma: a clinical and radiological analysis of 48 cases
Authors
Xiaoping Yi
Hang Cao
Haiyun Tang
Guanghui Gong
Zhongliang Hu
Weihua Liao
Lunquan Sun
Bihong T. Chen
Xuejun Li
Publication date
01-01-2019
Publisher
Springer Berlin Heidelberg
Published in
European Radiology / Issue 1/2019
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-018-5398-y

Other articles of this Issue 1/2019

European Radiology 1/2019 Go to the issue